Tuesday after the biotech company revealed intentions to submit a New Drug Application to the U.S. Food and Drug Authority (FDA) seeking speedy clearance for dordaviprone, a therapy for recurrent H3 K27M-mutantdiffuse glioma, Chimerix (NASDAQ:CMRX) more than doubled, rising over 220% on Tuesday.The corporation will ask Priority Review and wants to turn in the application by the end of the year. Data from Phase 2 and Phase 3 studies, showing a 28% objective response rate and a median response duration of 10.4 months, will be included into the NDA.
Over 2,000 U.S. patients yearly suffer from severe brain cancer known as recurrent H3 K27M-mutant diffuse glioma. For this disorder, no FDA-approved treatment exists right now. Should the application be approved Priority Review Chimerix plans to start the treatment in the United States by the third quarterof 2025.
To speed patient access to the treatment, Chimerix said it had interacted withFDA, disease experts, and advocates. To assess safety and pharmacokinetics, the business is also doing Phase 1 research on another therapy, ONC206.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.